Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NEULAND LABS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NEULAND LABS Mar-23 |
ADCOCK INGRAM Jun-14 |
NEULAND LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,004 | 320 | - | |
Low | Rs | 966 | 231 | - | |
Sales per share (Unadj.) | Rs | 928.4 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 127.4 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 168.6 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
Avg Dividend yield | % | 0.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 774.8 | 74.8 | - | |
Shares outstanding (eoy) | m | 12.83 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.6 | 2.9 | 55.3% | |
Avg P/E ratio | x | 11.7 | -11.5 | -101.5% | |
P/CF ratio (eoy) | x | 8.8 | -13.9 | -63.6% | |
Price / Book Value ratio | x | 1.9 | 3.7 | 52.0% | |
Dividend payout | % | 7.8 | 0 | - | |
Avg Mkt Cap | Rs m | 19,052 | 46,551 | 40.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 2,018 | 2,922 | 69.1% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,912 | 16,089 | 74.0% | |
Other income | Rs m | 97 | 113 | 86.5% | |
Total revenues | Rs m | 12,009 | 16,201 | 74.1% | |
Gross profit | Rs m | 2,718 | -2,788 | -97.5% | |
Depreciation | Rs m | 528 | 694 | 76.0% | |
Interest | Rs m | 131 | 436 | 30.0% | |
Profit before tax | Rs m | 2,157 | -3,806 | -56.7% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 522 | 238 | 219.6% | |
Profit after tax | Rs m | 1,635 | -4,054 | -40.3% | |
Gross profit margin | % | 22.8 | -17.3 | -131.7% | |
Effective tax rate | % | 24.2 | -6.2 | -387.4% | |
Net profit margin | % | 13.7 | -25.2 | -54.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,609 | 11,784 | 64.6% | |
Current liabilities | Rs m | 4,390 | 6,630 | 66.2% | |
Net working cap to sales | % | 27.0 | 32.0 | 84.4% | |
Current ratio | x | 1.7 | 1.8 | 97.5% | |
Inventory Days | Days | 6 | 111 | 5.7% | |
Debtors Days | Days | 1,109 | 124 | 894.4% | |
Net fixed assets | Rs m | 8,189 | 6,869 | 119.2% | |
Share capital | Rs m | 129 | 75 | 172.7% | |
Net worth | Rs m | 9,941 | 12,628 | 78.7% | |
Long term debt | Rs m | 742 | 4,438 | 16.7% | |
Total assets | Rs m | 15,798 | 23,855 | 66.2% | |
Interest coverage | x | 17.5 | -7.7 | -226.5% | |
Debt to equity ratio | x | 0.1 | 0.4 | 21.3% | |
Sales to assets ratio | x | 0.8 | 0.7 | 111.8% | |
Return on assets | % | 11.2 | -15.2 | -73.7% | |
Return on equity | % | 16.4 | -32.1 | -51.2% | |
Return on capital | % | 21.4 | -19.8 | -108.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,372 | 1,373 | 172.7% | |
From Investments | Rs m | -615 | -422 | 145.8% | |
From Financial Activity | Rs m | -1,358 | 4,028 | -33.7% | |
Net Cashflow | Rs m | 403 | 4,979 | 8.1% |
Compare NEULAND LABS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NEULAND LABS With: SYNCOM FORMULATIONS MEDICAMEN BI GSK PHARMA PARMAX PHARMA SUPRIYA LIFESCIENCE
After opening the negative note, Indian share markets continued the downtrend as the session progressed and ended the day weak.